Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elodie Bôle-Richard"'
Autor:
Margaux Poussard, Laure Philippe, Maxime Fredon, Elodie Bôle‐Richard, Sabeha Biichle, Florian Renosi, Sophie Perrin, Marie Kroemer, Samuel Limat, Francis Bonnefoy, Etienne Daguindau, Eric Deconinck, Bérengère Gruson, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre
Publikováno v:
eJHaem, Vol 2, Iss 1, Pp 125-130 (2021)
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before co
Externí odkaz:
https://doaj.org/article/3786b6a3b47b4c46940e845d3bc1b435
Autor:
Laure Philippe, Adam Ceroi, Elodie Bôle-Richard, Alizée Jenvrin, Sabeha Biichle, Sophie Perrin, Samuel Limat, Francis Bonnefoy, Eric Deconinck, Philippe Saas, Francine Garnache-Ottou, Fanny Angelot-Delettre
Publikováno v:
Haematologica, Vol 102, Iss 11 (2017)
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promi
Externí odkaz:
https://doaj.org/article/06f07cfd6ea84c7b824101eccd0b827d
Autor:
Lucie Bouquet, Elodie Bôle-Richard, Walid Warda, Mathieu Neto Da Rocha, Rim Trad, Clémentine Nicod, Rafik Haderbache, Delphine Genin, Christophe Ferrand, Marina Deschamps
Publikováno v:
Gene Therapy.
Even if adoptive cell transfer (ACT) has already shown great clinical efficiency in different types of disease, such as cancer, some adverse events consistently occur, and suicide genes are an interesting system to manage these events. Our team devel
Autor:
Blandine Caël, Elodie Bôle-Richard, Jeanne Galaine, Olivier Adotevi, Francine Garnache-Ottou, François Aubin
Publikováno v:
British Journal of Dermatology.
Our preliminary results demonstrate the feasibility of CAR123 production from patients’T-cells with AID and IMID and their in vitro cytotoxicity towards circulating autologous pDCs.
Autor:
Maxime Fredon, Margaux Poussard, Sabeha Biichle, Francis Bonnefoy, Evan Seffar, Elodie Bôle-Richard, Florian Renosi, Romain Boidot, François Anna, Maria Loustau, Julien Caumartin, Philippe Saas, Eric Deconinck, Etienne Daguindeau, Xavier Roussel, Olivier Adotevi, Fanny Angelot-Delettre, Jeanne Galaine, Francne Garnache-Ottou
Background: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive malignant hemopathy characterized by constant overexpression of the CD123 antigen on 100% of blasts identifying CD123 as an antigenic target for the development of adop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ab2c72901627db0e0e2e8e519e9a84c
https://doi.org/10.21203/rs.3.rs-1646566/v1
https://doi.org/10.21203/rs.3.rs-1646566/v1
Autor:
Blandine Caël, Jeanne Galaine, Isabelle Bardey, Chrystel Marton, Maxime Fredon, Sabeha Biichle, Margaux Poussard, Yann Godet, Fanny Angelot-Delettre, Christophe Barisien, Christophe Bésiers, Olivier Adotevi, Fabienne Pouthier, Francine Garnache-Ottou, Elodie Bôle-Richard
Publikováno v:
Cancers; Volume 14; Issue 13; Pages: 3168
Chimeric Antigen Receptor (CAR) therapy has led to great successes in patients with leukemia and lymphoma. Umbilical Cord Blood (UCB), stored in UCB banks, is an attractive source of T cells for CAR-T production. We used a third generation CD123 CAR-
Publikováno v:
Cancers. 14:2287
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia derived from plasmacytoid dendritic cells (pDCs). It is associated with a remarkably poor prognosis and unmet need for better therapies. Recently, the first-in-cla
Autor:
Olivier Adotevi, François Anna, Elodie Bole-Richard, Joel LeMaoult, Marie Escande, Martin Lecomte, Jean-Marie Certoux, Philippe Souque, Francine Garnache, Pierre Langlade-Demoyen, Maria Loustau, Julien Caumartin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background CAR-T cells immunotherapy is a breakthrough in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and B-cell malignancies. However, CAR-T therapies face major hurdles such as the lack of tumor-specific a
Externí odkaz:
https://doaj.org/article/55a6eb05e4d549b48790582481d89419